Literature DB >> 26191241

Inhibitory effect of midkine-binding peptide on tumor proliferation and migration.

Hui-Lian Huang1, Jian-Fen Shen2, Li-Shan Min1, Jin-Liang Ping3, Yong-Liang Lu4, Li-Cheng Dai1.   

Abstract

BACKGROUND: To investigate the inhibitory effect of midkine-binding peptides on human umbilical vein endothelial cells (HUVECs) proliferation and angiogenesis of xenograft tumor.
METHODS: The midkine-binding peptides were panned by Ph.D.-7(™) Phage Display Peptide Library Kit, and the specific binding activities of positive clones to target protein were examined by phage ELISA. The effect of midkine-binding peptides on proliferation of HUVECs was confirmed by MTT test. The xenograft tumor model was formed in BALB/c mice with the murine hepatocarcinoma cells H22 (H22). Microvessel density (MVD) was analyzed by immunohistochemistry of factor VIII staining.
RESULTS: Midkine-binding peptides have the inhibitory effects on tumor angiogenesis, a proliferation assay using human umbilical vein endothelial cells (HUVECs) indicated that particular midkine-binding peptides significantly inhibited the proliferation of the HUVECs. Midkine-binding peptides were also observed to efficiently suppress angiogenesis induced by murine hepatocarcinoma H22 cells in BALB/c nude mice.
CONCLUSION: The midkine-binding peptides can inhibit solid tumor growth by retarding the formation of new blood vessels. The results indicate that midkine-binding peptides may represent potent anti-angiogenesis agents in vivo.

Entities:  

Keywords:  Midkine; angiogenesis; peptide

Mesh:

Substances:

Year:  2015        PMID: 26191241      PMCID: PMC4503112     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  37 in total

1.  Keeping in touch with angiogenesis.

Authors:  L P Aiello
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

Review 2.  Angiogenesis in bladder cancer--prognostic marker and target for future therapy.

Authors:  Edward H Streeter; Adrian L Harris
Journal:  Surg Oncol       Date:  2002-06       Impact factor: 3.279

Review 3.  Antiangiogenic strategies and agents in clinical trials.

Authors:  L Rosen
Journal:  Oncologist       Date:  2000

4.  Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells.

Authors:  Y Takei; K Kadomatsu; S Matsuo; H Itoh; K Nakazawa; S Kubota; T Muramatsu
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

Review 5.  Role of the tumor microenvironment in mediating response to anti-angiogenic therapy.

Authors:  Y D Jung; S A Ahmad; Y Akagi; Y Takahashi; W Liu; N Reinmuth; R M Shaheen; F Fan; L M Ellis
Journal:  Cancer Metastasis Rev       Date:  2000       Impact factor: 9.264

6.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.

Authors:  A Eberhard; S Kahlert; V Goede; B Hemmerlein; K H Plate; H G Augustin
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

Review 7.  Angiogenesis in cancer and other diseases.

Authors:  P Carmeliet; R K Jain
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

8.  Midkine, a retinoic acid-inducible growth/differentiation factor: immunochemical evidence for the function and distribution.

Authors:  H Muramatsu; H Shirahama; S Yonezawa; H Maruta; T Muramatsu
Journal:  Dev Biol       Date:  1993-10       Impact factor: 3.582

9.  Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues.

Authors:  R I Garver; C S Chan; P G Milner
Journal:  Am J Respir Cell Mol Biol       Date:  1993-11       Impact factor: 6.914

Review 10.  Antibodies and peptides in cancer therapy.

Authors:  Jayant J Khandare; Tamara Minko
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2006       Impact factor: 4.889

View more
  4 in total

Review 1.  Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.

Authors:  Cem Simsek; Sebnem Selek; Meltem Koca; Ibrahim Celal Haznedaroglu
Journal:  SAGE Open Med       Date:  2017-07-27

Review 2.  Current Status of Gene Therapy in Hepatocellular Carcinoma.

Authors:  Saranya Chidambaranathan Reghupaty; Devanand Sarkar
Journal:  Cancers (Basel)       Date:  2019-08-28       Impact factor: 6.639

Review 3.  Antineoplastic Effects of Ankaferd Hemostat.

Authors:  Umit Yavuz Malkan; Ibrahim Celalettin Haznedaroglu
Journal:  Biomed Res Int       Date:  2022-08-02       Impact factor: 3.246

4.  Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma.

Authors:  Petra Schneiderova; Tomas Pika; Petr Gajdos; Regina Fillerova; Pavel Kromer; Milos Kudelka; Jiri Minarik; Tomas Papajik; Vlastimil Scudla; Eva Kriegova
Journal:  Oncotarget       Date:  2016-08-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.